AR059696A1 - Medicamentos que contienen fluoroquinolonas - Google Patents

Medicamentos que contienen fluoroquinolonas

Info

Publication number
AR059696A1
AR059696A1 ARP070100842A ARP070100842A AR059696A1 AR 059696 A1 AR059696 A1 AR 059696A1 AR P070100842 A ARP070100842 A AR P070100842A AR P070100842 A ARP070100842 A AR P070100842A AR 059696 A1 AR059696 A1 AR 059696A1
Authority
AR
Argentina
Prior art keywords
fluoroquinolones
medicines containing
quaternary ammonium
containing fluoroquinolones
fluoroquinolone
Prior art date
Application number
ARP070100842A
Other languages
English (en)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38171208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059696(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of AR059696A1 publication Critical patent/AR059696A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de compuestos de amonio cuaternario para evitar las precipitaciones de fluoroquinolonas a partir de sus disoluciones, así como a medicamentos estables tolerables, particularmente adecuados para aplicacion parenteral, que contienen en forma disuelta una fluoroquinolona y un compuesto de amonio cuaternario.
ARP070100842A 2006-03-08 2007-03-01 Medicamentos que contienen fluoroquinolonas AR059696A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006010643A DE102006010643A1 (de) 2006-03-08 2006-03-08 Arzneimittel enthaltend Fluorchinolone

Publications (1)

Publication Number Publication Date
AR059696A1 true AR059696A1 (es) 2008-04-23

Family

ID=38171208

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100842A AR059696A1 (es) 2006-03-08 2007-03-01 Medicamentos que contienen fluoroquinolonas

Country Status (31)

Country Link
US (1) US10231925B2 (es)
EP (2) EP1993510A1 (es)
JP (1) JP5584418B2 (es)
KR (2) KR20150046367A (es)
CN (2) CN101394836B (es)
AR (1) AR059696A1 (es)
AU (1) AU2007291622B2 (es)
BR (1) BRPI0708613B1 (es)
CA (1) CA2645037C (es)
CR (1) CR10270A (es)
DE (1) DE102006010643A1 (es)
DK (1) DK2340809T3 (es)
EC (1) ECSP088716A (es)
ES (1) ES2542206T3 (es)
GT (1) GT200800173A (es)
HU (1) HUE025044T2 (es)
IL (1) IL193429A0 (es)
MX (1) MX2008011344A (es)
MY (1) MY152885A (es)
NZ (1) NZ571046A (es)
PE (1) PE20071021A1 (es)
PL (1) PL2340809T3 (es)
PT (1) PT2340809E (es)
RU (1) RU2527327C2 (es)
SI (1) SI2340809T1 (es)
SV (1) SV2008003014A (es)
TW (1) TWI494105B (es)
UA (1) UA96753C2 (es)
UY (1) UY30191A1 (es)
WO (1) WO2008025380A1 (es)
ZA (1) ZA200807484B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1405890B2 (en) 2001-05-15 2017-03-15 Eurokera Thermochromic material
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
WO2010069493A1 (de) * 2008-12-18 2010-06-24 Bayer Animal Health Gmbh Verbesserte wirkstoffkombination enthaltend ein antibiotikum und einen nichtsteroidalen entzündungshemmer (nsaid)
EP2332916A3 (en) 2009-11-19 2011-08-03 Krka Tovarna Zdravil, D.D., Novo Mesto A process for a preparation of marbofloxacin and intermediate thereof
CN101716141B (zh) * 2010-01-20 2011-11-30 白求恩医科大学制药厂 一种氟罗沙星注射液及其制备方法
GB2480276A (en) * 2010-05-11 2011-11-16 Michael Hilary Burke Process for the preparation of an aqueous injectable enrofloxacin antimicrobial formulation
RU2682171C2 (ru) * 2016-10-11 2019-03-15 Закрытое Акционерное Общество "Биологические Исследования И Системы" (Зао "Бис") Фармацевтическая комбинированная композиция для лечения гнойных ран на основе фторхинолонов (варианты)
WO2018083675A1 (en) * 2016-11-07 2018-05-11 Jubilant Life Sciences Limited Synergistic antimicrobial compositions
CA3053211A1 (en) * 2017-02-13 2018-08-16 Bayer Animal Health Gmbh Liquid composition containing pradofloxacin and antioxidants
WO2019023842A1 (en) 2017-07-31 2019-02-07 Dow Silicones Corporation MOISTURE CURING COMPOSITIONS
KR20200037276A (ko) 2017-07-31 2020-04-08 다우 실리콘즈 코포레이션 수분 경화성 조성물
CN111620901B (zh) * 2020-06-08 2023-03-21 蚌埠医学院第二附属医院 一种含硅氧烷基的氟喹诺酮化合物、其制备方法及用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
US4551456A (en) * 1983-11-14 1985-11-05 Merck & Co., Inc. Ophthalmic use of norfloxacin and related antibiotics
AT392789B (de) 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
IN166416B (es) 1985-09-18 1990-05-05 Pfizer
DE3713672A1 (de) 1987-04-24 1988-11-17 Bayer Ag Verfahren zur herstellung von parenteral verabreichbaren chinoloncarbonsaeuren
DE3831514A1 (de) 1988-09-16 1990-03-22 Bayer Ag Ph-neutrale waessrige loesungen von chinoloncarbonsaeuren
US5225413A (en) 1988-09-16 1993-07-06 Bayer-Aktiengesellschaft pH-neutral aqueous solutions of quinolone-carboxylic acids
JP2832535B2 (ja) 1989-04-04 1998-12-09 富山化学工業株式会社 キノロンカルボン酸またはその塩の可溶化法
WO1991009616A1 (en) 1989-12-22 1991-07-11 Yale University Quinolone antibiotics encapsulated in lipid vesicles
ES2102393T3 (es) 1989-12-29 1997-08-01 Abbott Lab Complejos de acido quinolona carboxilico--ion metalico--acido.
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
DE69224071T2 (de) 1991-09-17 1998-05-07 Alcon Lab Inc Chinolan-antibiotika und polystyrolsulfonat enthaltende zusammensetzungen
NZ501160A (en) 1995-12-21 2001-10-26 Pfizer Subcutaneously injectable quinolone formulations with zinc or magnesium compounds and a co-solvent
US6323213B1 (en) 1996-02-23 2001-11-27 Bayer Aktiengesellschaft Possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives
WO1998018492A1 (fr) 1996-10-25 1998-05-07 Yoshitomi Pharmaceutical Industries Ltd. Procede pour empecher la precipitation de medicaments
GB9714218D0 (en) 1997-07-04 1997-09-10 Allied Therapeutics Ltd Peritoneal dialysis fluid
DE19729879C2 (de) * 1997-07-11 1999-07-08 Mann Gerhard Chem Pharm Fab Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin
US6387928B1 (en) 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
SK286420B6 (sk) * 1997-09-15 2008-09-05 The Procter & Gamble Company Zlúčenina so štruktúrou chinolónu, farmaceutický prostriedok s jej obsahom a jej použitie
US6605751B1 (en) 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making
ID21415A (id) 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
DE19918324A1 (de) * 1999-04-22 2000-10-26 Mann Gerhard Chem Pharm Fab Pharmazeutische Zusammensetzung wirksam gegen durch Bakterien, Viren, Pilze, Hefen und Protozoen verursachte Krankheitszustände
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
PL201130B1 (pl) 1999-09-24 2009-03-31 Alcon Inc Kompozycje zawiesinowe zawierające ciprofloksacynę i deksametazon do podawania miejscowego do oczu, uszu lub nosa
WO2004087043A2 (en) * 2003-02-21 2004-10-14 Sun Pharmaceutical Industries Limited Stable ophthalmic formulation containing an antibiotic and a corticosteroid
DE10312346A1 (de) 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
RU2248199C1 (ru) * 2003-06-02 2005-03-20 Открытое Акционерное Общество "Акционерное Курганское общество медицинских препаратов и изделий "Синтез" (ОАО "Синтез") Глазные капли и способ их получения
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
DE102004015981A1 (de) 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
CN102499928A (zh) * 2004-08-13 2012-06-20 先灵-普劳有限公司 包含抗菌素、三唑和皮质类固醇的药物制剂

Also Published As

Publication number Publication date
US10231925B2 (en) 2019-03-19
JP5584418B2 (ja) 2014-09-03
EP2340809A2 (de) 2011-07-06
DK2340809T3 (en) 2015-07-20
AU2007291622A1 (en) 2008-03-06
EP2340809A3 (de) 2012-09-19
ES2542206T3 (es) 2015-08-03
CN101394836B (zh) 2017-08-29
BRPI0708613B1 (pt) 2021-10-19
JP2009529015A (ja) 2009-08-13
PE20071021A1 (es) 2007-11-25
SV2008003014A (es) 2010-05-17
KR20080106253A (ko) 2008-12-04
CR10270A (es) 2009-03-18
ECSP088716A (es) 2008-11-27
CA2645037A1 (en) 2008-03-06
RU2527327C2 (ru) 2014-08-27
TW200810756A (en) 2008-03-01
WO2008025380A1 (de) 2008-03-06
GT200800173A (es) 2009-09-14
NZ571046A (en) 2012-05-25
CA2645037C (en) 2016-06-28
EP1993510A1 (de) 2008-11-26
RU2008139635A (ru) 2010-04-20
ZA200807484B (en) 2009-11-25
SI2340809T1 (sl) 2015-08-31
PT2340809E (pt) 2015-08-28
DE102006010643A1 (de) 2007-09-13
BRPI0708613A2 (pt) 2011-06-07
IL193429A0 (en) 2009-05-04
EP2340809B1 (de) 2015-04-15
PL2340809T3 (pl) 2015-09-30
AU2007291622B2 (en) 2013-08-01
CN104208064A (zh) 2014-12-17
KR20150046367A (ko) 2015-04-29
UA96753C2 (ru) 2011-12-12
CN101394836A (zh) 2009-03-25
MY152885A (en) 2014-11-28
UY30191A1 (es) 2007-10-31
US20100009979A1 (en) 2010-01-14
TWI494105B (zh) 2015-08-01
MX2008011344A (es) 2008-11-12
HUE025044T2 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
AR059696A1 (es) Medicamentos que contienen fluoroquinolonas
DK2719388T3 (da) Borholdige små molekyler som antiinflammatoriske midler
CO6491052A2 (es) Compuestos espirociclicos que contienen notrogeno y su uso medicinal
CL2012001348A1 (es) Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry.
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
AR067815A1 (es) Composicion de recubrimiento electrodepositable que contiene una guanidina ciclica
BRPI0920229A2 (pt) modelo de memória para atributos de hardware dentro de um sistema de memória transacional
BR112012026338A2 (pt) novos derivados de 3,3-dimetil tetrahidroquinolina
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
DK2254549T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyol-komplekser
ECSP11011258A (es) Pirimidinas fusionadas
BRPI0921365A2 (pt) cartucho, um dispensador de produtos farmacêuticos que contém o cartucho, bem como as aplicações do catucho e do dispensador de produtos farmacêuticos.
ME01459B (me) Postupak za doziranje medikamenata
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
EA200900397A1 (ru) Новые соединения диосметина, способ их получения и фармацевтические композиции, которые их содержат
ECSP11011494A (es) Preparación de solido
PH12015502178A1 (en) Pyridinylpyrazoloquinoline compound
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
ECSP088722A (es) Formulaciones medicamentosas que contienen fluoroquinolonas
CL2017000069A1 (es) Derivado de hidantoina.
BR112012013319A8 (pt) derivados espiro azacíclicos
CL2011000292A1 (es) Compuestos derivados de enfumafungina y sus sales farmaceuticamente aceptables, como inhibidores de (1,3)-beta-d-glucano sintasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
BRPI0821116B8 (pt) composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo
EA201070194A1 (ru) Стабильная жидкая фармацевтическая композиция на основе тразодона
BRPI0810871A2 (pt) Composto, processo de preparação de um composto, composição farmacêutica e utilização de um composto.

Legal Events

Date Code Title Description
FB Suspension of granting procedure